Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Diagnostics Launches Two Cancer Drug Testing Agents In Japan

This article was originally published in PharmAsia News

Executive Summary

Roche Diagnostics plans to launch the biomarker KRASfor Merck Serono's colon cancer drug Erbitux (cetuximab) in March. KRAS will be used to test genotypes when administering colon cancer drugs to decide the relationship between genotypes and drug efficacy. The company also plans to launches EGFRtesting for lung cancer drugs this summer, which will be used to assess efficacy of AstraZeneca's Iressa (gefitinib) and Chugai's Tarceva (erlotinib). (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel